文献速递皮肤感染药疹与重症皮肤不良反应

SARS-CoV-2疫苗接种后皮肤反应:西班牙全国横断面研究405例

Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
PubMed 文献 · Br J Dermatol · 2021-09-21

该西班牙全国横断面研究纳入405例SARS-CoV-2疫苗接种后21天内出现皮肤反应的患者,经皮肤科医生面诊和临床照片收集信息,共识分类皮肤反应模式。多数反应轻至中度且自限,但21%被分类为严重/非常严重,81%需要治疗。

要点

  • 接种SARS-CoV-2疫苗后皮肤反应表现多样,以注射部位反应最常见。
  • 21%的反应被分类为严重/非常严重,81%需要治疗。

核心结论

  • SARS-CoV-2疫苗接种后皮肤反应呈异质性,多数轻至中度且自限,但存在严重/非常严重反应。

研究设计与样本

  • 西班牙全国横断面研究,纳入405例接种任何剂次获批疫苗后21天内出现皮肤反应的患者,经皮肤科医生面诊和在线调查收集信息。

临床怎么用

  • 临床医生应认识SARS-CoV-2疫苗接种后多种皮肤反应模式,多数轻至中度自限,可安抚患者,但需警惕严重/非常严重反应并及时治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cutaneous reactions after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are poorly characterized. OBJECTIVE: To describe and classify cutaneous reactions after SARS-CoV-2 vaccination. METHODS: A nationwide Spanish cross-sectional study was conducted. We included patients with cutaneous reactions within 21 days of any dose of the approved vaccines at the time of the study. After a face-to-face visit with a dermatologist, information on cutaneous reactions was collected via an online professional survey and clinical photographs were sent by email. Investigators searched for consensus on clinical patterns and classification. RESULTS: From 16 February to 15 May 2021, we collected 405 reactions after vaccination with the BNT162b2 (Pfizer-BioNTech; 40·2%), mRNA-1273 (Moderna; 36·3%) and AZD1222 (AstraZeneca; 23·5%) vaccines. Mean patient age was 50·7 years and 80·2% were female. Cutaneous reactions were classified as injection site ('COVID arm', 32·1%), urticaria (14·6%), morbilliform (8·9%), papulovesicular (6·4%), pityriasis rosea-like (4·9%) and purpuric (4%) reactions. Varicella zoster and herpes simplex virus reactivations accounted for 13·8% of reactions. The COVID arm was almost exclusive to women (95·4%). The most reported reactions in each vaccine group were COVID arm (mRNA-1273, Moderna, 61·9%), varicella zoster virus reactivation (BNT162b2, Pfizer-BioNTech, 17·2%) and urticaria (AZD1222, AstraZeneca, 21·1%). Most reactions to the mRNA-1273 (Moderna) vaccine were described in women (90·5%). Eighty reactions (21%) were classified as severe/very severe and 81% required treatment. CONCLUSIONS: Cutaneous reactions after SARS-CoV-2 vaccination are heterogeneous. Most are mild-to-moderate and self-limiting, although severe/very severe reactions are reported. Knowledge of these reactions during mass vaccination may help healthcare professionals and reassure patients.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2021. PMID: 34254291. doi:10.1111/bjd.20639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。